ClinicalTrials.gg
CompletedNCT07840495LLLT IN TMDUpdated Oct 1, 2026

The Efficacy of Low-level Laser Therapy (LLLT) as an Adjunct Treatment for Pain and Functional Outcomes in Temporomandibular Disorders (TMD)

An interventional study of LLLT and Sham (No LLLT) in Low Level Laser Therapy, Temporomandibular Joint Disorders and Pain, sponsored by University of Malaya. Completed at 1 site in Malaysia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by University of Malaya · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Jan 2024, registered Sep 2026).
Updated Sep 25, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the effectiveness of low-level laser therapy (LLLT) as an adjunct treatment in patients aged 18 years and older diagnosed with temporomandibular disorders (TMD).

The main questions it aims to answer are:

  1. Does LLLT improve pain intensity during muscle palpation and mandibular movements?
  2. Does LLLT improve functional outcomes, such as maximum mouth opening, lateral excursions, and protrusive movements?

Researchers will compare active LLLT alongside conservative treatment to a sham laser with conservative treatment to see if the active laser provides significantly greater reductions in pain and improvements in jaw function.

Participants will follow a standardized conservative treatment protocol, which includes taking ibuprofen and muscle relaxants, applying moist heat therapy, and eating a soft diet. Receive either an active laser treatment or a sham (placebo) laser treatment on identified tender points for 38 seconds per point, given in six sessions over two weeks. Undergo pain and functional assessments at baseline, after each treatment session, and at Day 14 and Day 30 follow-up visits.

Read the detailed description

This randomized controlled trial included 30 patients diagnosed with TMD based on Axis I of the DC/ TMD criteria. Participants were allocated into two groups: 15 received LLLT alongside conservative treatment, while 15 received sham laser with conservative treatment. Pain was evaluated using the Visual Analogue Scale (VAS) during palpation and mandibular movement, while function was evaluated by measuring mouth opening, lateral excursions and protrusion. The LLLT group was treated with a 940 nm diode laser (10 J/cm2, 0.3 W, 1.13 cm2 spot size) applied to tender points for 38 seconds per point over six sessions within two weeks. The placebo group received sham laser application. Assessments were conducted at baseline, after each session and at Day 14 and Day 30 follow-ups.

02

Conditions studied

  • Low Level Laser Therapy
  • Temporomandibular Joint Disorders
  • Pain
  • Physical Therapy

Keywords

  • Low level laser therapy
  • temporomandibular joint disorders
  • pain
  • physical therapy
03

In context

Temporomandibular Joint Disorders

593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.

This study's enrollment of 30 is below the median of 45 across 417 interventional studies indexed under Temporomandibular Joint Disorders.

Browse Temporomandibular Joint Disorders studies →

Lead sponsor

University of Malaya is the lead sponsor of 285 studies on the registry; 59 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 18 and above
  2. Patients diagnosed with TMD utilizing Axis I of the DC/TMD
  3. Patients diagnosed with TMD irrespective of the severity as screened utilizing the Fonseca Anamnestic Index (FAI) questionnaire form (APPENDIX D)
  4. American Association of Anesthesiologists (ASA) Physical Status Classification I-II
  5. Class I occlusion/malocclusion
  6. Natural dentition patient with at least one pair of occluding posterior teeth on each side of the mandible

Exclusion criteria

Exclusion Criteria:

  1. Patients who refuse participation/do not consent to the study
  2. Patients presenting with any lesion or pathology over the TMJ region
  3. Patients presented with TMD-like signs and symptoms secondary to non-TMJ origin (pain or infection of odontogenic origin, ear origin, neuralgia, migraine, atypical facial pain, etc.)
  4. Patients that are presented with active infection involving the orofacial region
  5. Patients with psychiatric and neurological disorders as confirmed by medical practitioners.
  6. Patients with systemic or disorders affecting the masticatory system, bones, and joints (rheumatoid arthritis, osteoarthritis)
  7. Patients that are for the use of LLLT (malignant disease, ongoing radiotherapy, thyroid gland disease, epilepsy, light sensitivity, hemophilia, and other blood and clotting diseases, etc.)
  8. TMD patients receiving physical or psychological treatment, and those who have been using muscle relaxants, anti-inflammatory agents (for at least seven days before study begins) or an occlusal appliance
  9. Patients with a history of facial bone fractures
  10. Patients on fixed orthodontic appliances, history of orthognathic surgery, or TMJ surgery
  11. Patients with occlusal interferences, removable partial or total denture wearers, and fixed prostheses that are affecting patients' occlusion
  12. Patients with an allergy to, or contraindication for, the use of NSAIDs
  13. Pregnant patients
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Patients with TMDs

    The LLLT group was treated with a 940 nm diode laser (10 J/cm2, 0.3 W, 1.13 cm2 spot size) applied to tender points for 38 seconds per point over six sessions within two weeks

    Device: LLLT

  • Sham comparator
    Patient with TMDs + Sham treatment

    Patients with TMDs and given Sham treatment

    Procedure: Sham (No LLLT)

Interventions

  • DeviceLLLT

    The LLLT group was treated with a 940 nm diode laser (10 J/cm2, 0.3 W, 1.13 cm2 spot size) applied to tender points for 38 seconds per point over six sessions within two weeks

  • ProcedureSham (No LLLT)

    Non activated LLLT applied to tender points for 38 seconds per point over six sessions within two weeks

06

What researchers measure

Primary outcomes

  1. Pain: VAS score

    Visual Analogue Scale (VAS): score 0 (no pain) to 10 (maximum pain) during muscle palpation and mandibular movement

    Time frame: Assessments were conducted at baseline, after each treatment session (S1 - S6) [three times weekly for two weeks], and at follow-up on Day 14 (D14) and Day 30 (D30) post-treatment.

Secondary outcomes

  1. Maximum pain-free mouth opening

    It is the measurement of the interincisal distance between the maxillary and mandibular reference teeth of the maximum mouth opening of the patient in millimeters - performed either without pain or, if the patient is already in pain, as wide as possible, without worsening the existing pain

    Time frame: Assessments were conducted at baseline, after each treatment session (S1 - S6), and at follow-up on Day 14 (D14) and Day 30 (D30) post-treatment.

  2. Maximum mouth opening with pain, unassisted

    It is the measurement of the interincisal distance between the maxillary and mandibular reference teeth with the patient opening their mouth as wide as possible, even if it causes pain.

    Time frame: Assessments were conducted at baseline, after each treatment session (S1 - S6), and at follow-up on Day 14 (D14) and Day 30 (D30) post-treatment.

  3. d) Maximum assisted mouth opening

    The maximum assisted mouth opening is then measured in millimeters as the interincisal distance between the upper and lower central incisors at this point.

    Time frame: Assessments were conducted at baseline, after each treatment session (S1 - S6), and at follow-up on Day 14 (D14) and Day 30 (D30) post-treatment.

  4. Right and Left lateral movement

    The patient is asked to slightly open their mouth and move the jaw as far to the right as possible, even if it causes pain. The distance, in millimeters, between the maxillary and mandibular midline reference points is recorded as the right lateral movement. Then repeat on the left side.

    Time frame: Assessments were conducted at baseline, after each treatment session (S1 - S6), and at follow-up on Day 14 (D14) and Day 30 (D30) post-treatment.

  5. Protrusive mandibular movement

    The patient is instructed to slightly open their mouth and move the jaw forward as far as possible, even if it causes pain. The measurement, in millimeters, is taken from the buccal surface of a mandibular tooth to the corresponding buccal surface of a maxillary tooth

    Time frame: Assessments were conducted at baseline, after each treatment session (S1 - S6), and at follow-up on Day 14 (D14) and Day 30 (D30) post-treatment.

07

Study locations

1 site
  • Faculty of Dentistry, Universiti Malaya, Malaysia
    Kuala Lumpur, Kuala Lumpur 50603, Malaysia
08

References and documents

Publications

  • 1. Li DTS, Leung YY. Temporomandibular disorders: current concepts and controversies in diagnosis and management. Diagnostics (Basel). 2021: 11: 459. doi:10.3390/diagnostics11030459 2. Zieliński G, Pająk-Zielińska B, Ginszt M. A meta-analysis of the global prevalence of temporomandibular disorders. J Clin Med. 2024: 13: 665. doi:10.3390/jcm13051365 3. Suvinen TI, Reade PC, Kemppainen P, Könönen M, Dworkin SF. Review of aetiological concepts of temporomandibular pain disorders: towards a biopsychosocial model for integration of physical disorder factors with psychological and psychosocial illness impact factors. Eur J Pain. 2005: 9: 613-633. doi:10.1016/j.ejpain.2005.01.012 4. Taylor DN, Winfield T, Wynd S. Low-level laser light therapy dosage variables vs treatment efficacy of neuromusculoskeletal conditions: a scoping review. J Chiropr Med. 2020: 19: 119-127. doi:10.1016/j.jcm.2020.06.002 5. Carrasco TG, Mazzetto MO, Mazzetto RG, Mestriner WJ. Low intensity laser therapy in temporomandibular disorder: a phase II double-blind study. Cranio. 2008: 26: 274-281. doi:10.1179/crn.2008.037 6. Çetiner S, Kahraman SA, Yücetaş S. Evaluation of low-level laser therapy in the treatment of temporomandibular disorders. Photomed Laser Surg. 2006: 24: 637-641. doi:10.1089/pho.2006.24.637 7. Fikácková H, Dostálová T, Navrátil L, Klaschka J. Effectiveness of low-level laser therapy in temporomandibular joint disorders: a placebo-controlled study. Photomed Laser Surg. 2007: 25: 297-303. doi:10.1089/pho.2007.2053 8. Díaz L, Restelli L, Valencia E, Atalay DI, Abarca JM, Gil AC, et al. Effectiveness of low-level laser therapy on temporomandibular disorders. A systematic review of randomized clinical trials. Photodiagnosis Photodyn Ther. 2025: 53: 104558. doi:10.1016/j.pdpdt.2025.104558 9. Aisaiti A, Zhou Y, Wen Y, Zhou W, Wang C, Zhao J, et al. Effect of photobiomodulation therapy on painful temporomandibular disorders. Sci Rep. 2021: 11: 9049. doi:10.1038/s41598-021-87265-0

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared to protect participant confidentiality and privacy. The informed consent approved by the Ethics Committee/Institutional Review Board (IRB) did not include explicit authorization from participants for secondary data sharing or broad external repository deposition. Furthermore, due to the granular nature of the clinical data collected, full de-identification cannot be guaranteed without risk of re-identification. Aggregate data, summary statistics, and primary outcomes will instead be made available through peer-reviewed publications.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in May 2025, 16 months.

Of 243 non-industry interventional studies with no phase under Temporomandibular Joint Disorders, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 21. This study's 16 months is above that.

Counting every sponsor, half of 247 studies reached it within 11 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Sep 25, 2026
StartActual
Jan 2, 2024
Primary completionActual
May 30, 2025
CompletionActual
Aug 30, 2025
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 25, 2026
Show all 2 updates
  1. Oct 1, 2026
    Minor edits only
    + 2 other changes: responsible party and design details
  2. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07840495
Responsible party
Tan Chuey Chuan (Associate Professor Dr, University of Malaya) — Principal investigator
First posted
Sep 25, 2026
Start date
Jan 2, 2024
Primary completion
May 30, 2025
Completion
Aug 30, 2025
Last update
Oct 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion